Pharma Pulse: Industry Backlash, GSK’s $2.2B Immunology Bet, and the Future of Wearables

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, more than 200 prominent organizations—including the American Academy of Pediatrics—are banding together to denounce the recent decision to cut the recommended childhood vaccine schedule from 17 to 11. The coalition warns that removing protections against diseases like hepatitis A and rotavirus ignores decades of safety data and risks a preventable public health crisis.
• In M&A news, GSK has entered a definitive $2.2 billion agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE) monoclonal antibody, ozureprubart, currently in phase IIb clinical development for prophylactic protection against food allergens. As of Jan. 20, 2026, IgE is the only approved systemic therapy that has displayed the ability to protect patients from both a harmful allergic and inflammatory immune response.
• Lastly, ten23 health and BD are teaming up to scale the BD Libertas wearable injector. The partnership is expected to provide biopharma companies with a product that offers the subcutaneous delivery of large-volume drugs, accelerating development, while lowering risk in complex injectable programs in the process.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.